Graham Capital Management’s Denali Therapeutics DNLI Stock Holding History

Graham Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	+15,669	New	+$322K	0.01%	788
2026 Q1	–	Sell	-18,121	Closed	-$299K	–	1244
2025 Q4	$299K	Sell	18,121 -21,198	-54%	-$358K	0.01%	855
2025 Q3	$571K	Sell	39,319 -25,480	-39%	-$366K	0.01%	568
2025 Q2	$907K	Buy	64,799 +21,794	+51%	+$307K	0.01%	608
2025 Q1	$585K	Buy	43,005 +22,299	+108%	+$427K	0.01%	742
2024 Q4	$422K	Buy	20,706 +8,941	+76%	+$229K	0.01%	805
2024 Q3	$343K	Buy	+11,765	New	+$292K	0.01%	740
2023 Q3	–	Sell	-31,611	Closed	-$933K	–	1071
2023 Q2	$933K	Buy	+31,611	New	+$889K	0.03%	383

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's DNLI Position: Q2 2026 in Review

Graham Capital Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 15,669 shares worth $403K. The stake represents 0.01% of the portfolio and ranks #788 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in DNLI as recently as Q4 2025.

Graham Capital Management first reported a position in DNLI in Q2 2023 and has held it in 8 quarters since. The position peaked at $933K in Q2 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Graham Capital Management held 15,669 shares of Denali Therapeutics worth $403K as of Q2 2026.
Denali Therapeutics was a new Graham Capital Management position in Q2 2026.
Denali Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #788 holding.
Graham Capital Management first reported a position in Denali Therapeutics in Q2 2023 and has held it in 8 quarters since.
Graham Capital Management's Denali Therapeutics position peaked at $933K in Q2 2023.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.